Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Gujarat Themis Biosyn Ltd ( (IN:GUJTHEM) ) is now available.
Gujarat Themis Biosyn Ltd has released an investor presentation detailing its planned asset purchase of Sanofi’s global anti-tuberculosis and anti-infective portfolio. The disclosure, made under SEBI’s listing regulations and shared with both BSE and NSE, signals a strategic expansion of the company’s product range, potentially strengthening its position in critical anti-infective therapies and enhancing its appeal to investors tracking growth in specialty pharma assets.
More about Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd is an India-based pharmaceutical company operating in the biosciences and bulk drugs space, with manufacturing facilities in Vapi, Gujarat, and a corporate office in Mumbai. The company focuses on producing specialty formulations and active pharmaceutical ingredients for regulated and emerging markets, supplying to larger global pharma players and institutional customers.
Average Trading Volume: 9,181
Technical Sentiment Signal: Buy
Current Market Cap: 36B INR
Find detailed analytics on GUJTHEM stock on TipRanks’ Stock Analysis page.